Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

SLCImmuno post elsewhere: slcimmuno Member Leve

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 1104)
Posted On: 06/18/2017 8:56:21 PM
Avatar
Posted By: someconcerns
Re: thefamilyman #34981
SLCImmuno post elsewhere:

Quote:
slcimmuno Member Level Sunday, 06/18/17 12:55:44 PM
Re: biodoc post# 186322
Post # of 186356

Thx for comments biodoc - always appreciated.

Agree: The Otezla efficacy bar -- around 30% PASI 75 -- is the one we're hoping to meet... or beat... plus in a shorter timeframe, 12 weeks instead of 16 weeks.

The PASI 90s, even PASI 100s, though, will be worth watching. IGA 1/0 (almost clear / clear) is closer to PASI 90 than PASI 75. See cites below, with the first article particularly insightful, great aggregate data on the Anti-TNFs and IL-17s.

Have to say Biologics are impressive in PsO unlike IBD - strong PASI 90s and better, and quick on uptake..... in a recent study, half of Cosentyx patient achieved PASI 75 at Week 4 vs. 20% of patients on Stelara. But biologics come w baggage ... costly... tens of thousands of dollars, response failures [30%], effect wanes over time [30%] and side effects.

That in the Ph2 P trial (admittedly small) 46% of the IGA 3s (moderate) saw at least a 2-pt drop suggests healthy PASI 90s might be in the offing, particularly with jump from 200mg to 300mg and 400mg. Severe PsO patients might even respond better. If we crush Otezla in almost/clearing PsO and encroach on some of the lower end biologics (Cosyntex a reach), watch out. Also am interested in seeing if the 300mg and 400mg suggests dosing could go even higher -- i.e. up to the 600mg Ziagen I think maxed out at.

I think the Interim is being done to whet appetites of interested parties. If Prurisol shows it is fast on the draw (maybe 20-25% PASI 75 by week 4 - 6... almost as good as the likes of Stelara) that will be a strong signal. The slope steep and yet to plateau. For comparison, it looks like Otezla had about 5% PASI 75 at week 4 and maybe 12% at week 6. I also assume IPIX will comment on efficacy trends in patients who've been on treatment longer than 6 weeks.

See Figure 4
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
http://www.jaad.org/article/S0190-9622(15)01494-2/fulltext

Hopeful we see 40-50% PASI 75s over 12 weeks, with healthy PASI 90s... again Otezla only 8% PASI 90 over 16 weeks. If P can be shown to equal or better Otezla in less time, perhaps even while suboptimally-dosed, then we've def gotta a Big Winner. If it gets into the biologics space, then we've got a Humongous Winner.




Treatment goals for psoriasis: Should PASI 90 become the standard of care?

http://www.actasdermo.org/en/treatment-goals-...015000505/
https://pdfs.semanticscholar.org/9a6e/d8ab224...b9922a.pdf

EXCERPT

"a PASI 75 response would associate to an absolute PASI around 5, compatible with a PGA score of 2, usually considered mild psoriasis (mild plaque elevation, light red coloration, predomination of fine scale). However PASI 90 response would equate to a PASI around 2, compatible with a PGA of 0/1 (almost clear).In this sense, PASI 90 response probably better reflects a “clear”/“almost clear” status than PASI 75."

//

The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.

https://www.ncbi.nlm.nih.gov/m/pubmed/24354461/

Whereas IGA/PGA 0/1 responder rates for earlier scales are strongly associated with PASI 75, the IGA 0/1 rate for the secukinumab 6-point scale was more robust, demonstrating a strong association with PASI 90, and the results for the 5-point IGA are expected to show the same association.




(3)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us